Beat The Denominator

Investors should consider Hims & Hers Health (HIMS) as a high-conviction play while it trades near $19, representing a significant disconnect from its strong fundamental growth. The company’s shift toward branded Novo Nordisk (NVO) GLP-1s and its avoidance of patent-infringing compounds may pave the way for a lucrative future partnership with Eli Lilly (LLY). With 95% recurring revenue and a recession-proof subscription model, HIMS is positioned as a core long-term holding for the 2030s. The recent acquisition of a peptide manufacturing facility provides a massive competitive moat, allowing the company to control its supply chain as the Peptide market expands. Ignore short-term macro volatility and focus on this transition from a telehealth provider to a vertically integrated personalized medicine powerhouse.

Investors should view MicroStrategy (MSTR) as a long-term growth play, as its aggressive share issuance is designed to increase Bitcoin holdings and secure a higher weighting in NASDAQ and S&P 500 indices. The current 1:1 Market Net Asset Value provides a strategic entry point for those betting on mandatory buying from passive index funds and the eventual reduction of short-selling pressure. For income-focused investors, the "Stretch" digital credit instrument offers a stable 11.5% yield that is structurally difficult for bears to short. This credit instrument is highly secured, maintaining a 3x Bitcoin backing that protects the yield even if the price of BTC drops by up to 66%. Monitor the emerging "Digital Credit" sector for new preferred instruments like SATA, which allow investors to generate fixed income from the Bitcoin ecosystem rather than just holding the volatile underlying asset.

Investors should look toward Nebius Group (NBIS) as a high-conviction value play, as it currently trades at a significant discount of roughly 0.5x forward sales despite having $4.5 billion in contracts. Avoid using leverage or margin on high-volatility "blue chips" like NVIDIA (NVDA) and Broadcom (AVGO), as their price swings are currently driven by global liquidity shifts rather than business fundamentals. For those seeking to "outsource" volatility, consider yield-focused instruments or assets like MicroStrategy (MSTR) that offer structured exposure to market movements. Maintain a cash reserve to capitalize on "freakout" dips in growth stocks like Hims & Hers (HIMS), which frequently experience rapid recoveries after irrational sell-offs. Focus on long-term fundamental value and ignore daily price noise caused by geopolitical rumors or macroeconomic "denominator" fluctuations.

Investors should consider MicroStrategy (MSTR) as a primary vehicle for Bitcoin exposure, specifically utilizing high-yield strategies like the MSTY ETF to capture the spread between Bitcoin’s projected returns and current yields. For long-term Bitcoin (BTC) security, ensure assets are moved to modern wallets created after 2015 to mitigate any theoretical risks from quantum computing. Monitor market liquidity closely, as a return to "normalcy" over the next six months could trigger an "iPhone moment" of exponential growth for MSTR-linked yield products. Avoid reacting to "Quantum FUD" or geopolitical sell-offs, which are viewed as temporary liquidity drains rather than structural failures of the underlying assets. While defensive stocks like Walmart (WMT) and AT&T (T) are currently outperforming, stabilized liquidity will serve as the primary signal to increase positions in high-growth crypto assets.

Investors should view the current "slow bleed" in innovation stocks like Tesla (TSLA), NVIDIA (NVDA), and Broadcom (AVGO) as a period of high volatility to endure rather than a reason to exit, as business fundamentals remain strong. Consider Hims & Hers Health (HIMS) and Nebius (NBIS) as potential high-growth opportunities that have been unfairly punished by recent market "noise" despite aggressive revenue projections. Avoid rotating into "safe haven" assets like Government Bonds or Banking stocks, as persistent inflation and rising oil prices could lead to further interest rate hikes that would crash bond prices. While Bitcoin (BTC) and MicroStrategy (MSTR) are currently trading like high-risk tech assets, they remain preferred long-term holdings over traditional hedges like gold or bonds. Focus your portfolio on companies with 50%+ top-line revenue growth that can outpace a potential recession, rather than overcrowded consumer staples like Walmart.

Investors should monitor MicroStrategy (MSTR) for a potential buying opportunity as the company pauses Bitcoin accumulation during its end-of-quarter "no-buy week." The MSTR common stock may temporarily underperform Bitcoin due to active share dilution, but this capital is being used to accretively grow their treasury at a premium. Consider the "Stretch" (STRC) preferred stock as it hits the $100 milestone, offering a high-conviction play on the company's evolving financial network. For diversified exposure, watch for the launch of the Strive Digital Credit ETF (DGCR), which is specifically designed for retirement accounts seeking yield from Bitcoin-backed corporate treasuries. Despite geopolitical volatility, Bitcoin (BTC) remains a resilient hold as high-profile endorsements and institutional integration continue to drive mainstream adoption.

Investors should prioritize Bitcoin (BTC) as a resilient "safe haven" asset that is currently outperforming traditional hedges like gold and bonds during market volatility. For high-yield income with lower price swings, consider MicroStrategy Preferred Shares (STRC), which offer an 11% tax-deferred yield and have shown extreme price stability near the $100 level. Alternatively, STRIDE junior debt allows you to lock in a higher yield of approximately 13.6%, providing a "paid to wait" strategy while the broader market remains uncertain. Monitor MicroStrategy (MSTR) closely for a potential Bitcoin purchase announcement, as the company appears to be holding cash to buy a deeper market dip. Avoid chasing traditional "Old World" assets like oil, gold, or value stocks like Walmart (WMT) and Costco (COST), as they are currently viewed as overextended or fundamentally weak.

The recent pullback in Hims & Hers Health (HIMS) from $27 to $19 represents a high-conviction buying opportunity, as the sell-off is driven by broader market volatility rather than company fundamentals. Trading at just 2x forward gross profit with 90% recurring revenue, the stock is undervalued for a business expanding into high-demand sectors like GLP-1 weight loss, peptides, and hormone replacement therapy. Investors should look toward the H2 2026 Eucalyptus acquisition, which is expected to add $450M in annual recurring revenue, as a major mid-term catalyst. While traditional healthcare providers like Oscar Health (OSCR) are raising prices by 30%, HIMS is positioned to capture market share as the low-cost leader in "consumerized" medicine. For those with a long-term horizon toward 2030, this entry point offers exposure to a disruptive telehealth platform that functions more like an essential subscription service than a discretionary expense.

Investors should consider MicroStrategy (MSTR) as a high-conviction play for amplified Bitcoin exposure, as it historically delivers 150% of the cryptocurrency's price movement with superior resilience compared to major tech stocks. For those seeking defensive income, the MicroStrategy Short Interest Volatility Yield ETF (STRC) offers a robust 11.5% yield and has demonstrated significant price stability during recent market downturns. Bitcoin (BTC) itself is maturing into a "safe haven" asset, making it a viable alternative to traditional equities as it decouples from standard "risk-off" sentiment. Given the macroeconomic risks of rising oil prices and high interest rates, shifting capital toward these "hard assets" is recommended over traditional high-yield corporate bonds. Closely monitor the 10-year Treasury yield; if it approaches 5%, further rotation out of traditional equities and into the Bitcoin ecosystem is likely to accelerate.

The current market disconnect has created a massive undervaluation in Hims & Hers Health (HIMS), which remains a high-conviction contrarian play due to its strong margins and Novo Nordisk partnership despite recent price declines. Similarly, SoFi Technologies (SOFI) and Oscar Health (OSCAR) are trading at irrationally low levels relative to their revenue growth, offering long-term entry points for patient investors willing to ignore macro volatility. To bypass traditional market sentiment risk, consider using Prediction Markets like Polymarket to bet directly on company earnings or clinical outcomes rather than stock price movements. In the digital asset space, focus on "token-denominated" growth by Staking assets to compound yield and insulate your portfolio from US Dollar debasement. For a structural play on platform adoption, the Hyperliquid (HYPE) token offers a unique deflationary mechanism where 97% of trading fees are used for buybacks to counteract market swings.

Investors should monitor MicroStrategy (MSTR/STRC) as a high-conviction "risk-on" asset that is showing relative strength against a declining Nasdaq, with a recent price target hit of $100. Because the company can execute share offerings after-hours to purchase more Bitcoin (BTC), watch for price volatility and accumulation signals outside of standard trading windows. Bitcoin remains a highly sensitive proxy for geopolitical stability, making it prone to instant $1,000 price swings based on news headlines regarding Middle East tensions. For contrarian investors, Hims & Hers Health (HIMS) presents a potential value play as the stock experiences "nonsensical" sell-offs despite solid fundamentals. Avoid traditional telecommunications like AT&T (T) due to looming disruption from satellite internet, and remain cautious on the Nasdaq as high oil prices and 7% mortgage rates create a difficult "risk-off" macro environment.

Consider a long position in Hims & Hers Health (HIMS) while it trades in the low $20 range, as the stock currently suffers from a valuation disconnect despite resolving all major legal and regulatory risks. The company’s new partnership to distribute branded Wegovy and Ozempic at aggressive price points ($149–$299) serves as a massive revenue catalyst that is not yet reflected in official financial guidance. Novo Nordisk (NVO) has shifted from a legal adversary to a strategic partner, validating HIMS as a legitimate, high-volume distribution channel for the GLP-1 weight loss market. Investors should view the current volatility in growth stocks like HIMS and SoFi Technologies (SOFI) as a potential "buy the fear" opportunity where revenue has scaled significantly while share prices remain stagnant. This setup offers a high-conviction entry point for those who believe the market is incorrectly pricing the transition of telehealth into the mainstream pharmaceutical supply chain.

Investors should view Bitcoin at the $70,000 level as a high-conviction buying opportunity, especially as market sentiment remains in "Fear" territory. For maximum upside, MicroStrategy (MSTR) remains the primary leveraged play, though investors should expect temporary price lags during active At-The-Market (ATM) share offerings. Those seeking a superior risk-adjusted return should accumulate STRK preferred shares to lock in an 8% fixed dividend and a perpetual call option before the company further limits issuance. For a "risk-off" store of value, STRC is an ideal choice as it trades near its $100 par value and is seeing rapid institutional adoption as collateral. Diversifying across these three instruments allows investors to capture Bitcoin's growth while balancing volatility through fixed yields and conversion rights.

Investors should consider Hims & Hers Health (HIMS) at the current $21 level, as the resolution of Novo Nordisk legal threats and FDA investigations makes the stock fundamentally undervalued. Celsius Holdings (CELH) presents a strong buying opportunity following a 15% price drop, as the brand’s "status" appeal among younger demographics remains insulated from generic Costco competition. Marathon Digital Holdings (MARA) is a high-conviction play for those betting on its transition from a Bitcoin miner to a data center provider, especially since recent gains from its Starwood partnership have been erased. While the broader market is rotating into defensive value plays like Walmart (WMT) and AT&T (T), these specific growth names offer significant upside due to irrational selling. Focus on these fundamental shifts rather than short-term technical breakdowns or macro volatility driven by rising mortgage rates.

Take advantage of weekend Bitcoin (BTC) volatility by buying the dip in related equities like MicroStrategy (MSTR) on Monday mornings, as BTC shows a bullish rotation away from Gold. Tesla (TSLA) is a high-conviction long-term play at current $380 levels, as the market is ignoring its massive pivot into semiconductor manufacturing and AI scaling. Nebius (NBIS) represents a significant market inefficiency; it remains "cheap" despite securing a $27 billion contract with Meta and a major NVIDIA partnership. For growth investors, Celsius Holdings (CELH) and Oscar Health (OSCR) are currently undervalued, with OSCR specifically poised for a fundamental breakout driven by upcoming 30% premium increases. While NVIDIA (NVDA) and other AI leaders are currently suppressed by geopolitical "macro madness," cooling inflation and a potential September rate cut suggest a strong recovery is ahead for these "left behind" assets.

Investors should view MicroStrategy (MSTR) share offerings as a buying opportunity rather than a negative, as the company’s $42 billion "21-21" plan is designed to acquire Bitcoin (BTC) at a premium that increases shareholder value. This massive three-year capital raise creates a significant "buy wall" for BTC, providing a strong price floor and a bullish catalyst for the underlying digital asset. Monitor the MSTR Market Net Asset Value (MNAV) with a target of 1.5, representing a logical 150% correlation to the price of Bitcoin. For fixed-income investors, the STRC (Stretch) credit instruments are expected to recover toward the 100 level as current macroeconomic uncertainty subsides. Position for a significant market rally in 2025, as the execution of these capital plans aligns with an expected clearing of geopolitical and economic "macro ceilings."

Investors should view MicroStrategy (MSTR) as a high-conviction leveraged play on Bitcoin (BTC), as the company continues to strategically dilute shares at a premium to acquire more cryptocurrency. Monitor MSTR for an imminent announcement regarding new Bitcoin purchases, which could serve as a short-term catalyst despite recent market volatility. With the Crypto Fear and Greed Index dropping rapidly, long-term investors should look for entry points in BTC if the market moves into "Extreme Fear" amid geopolitical tensions. For those seeking high income, the YieldMax MSTR Option Income Strategy ETF (MSTY) is expected to see yields rise toward 11% next month, though it remains highly sensitive to macro liquidity shocks. Maintain a defensive posture by monitoring energy prices and Middle East infrastructure risks, as rising oil costs could further delay Federal Reserve rate cuts and pressure risk assets.

Accumulate Nebius (NBIS) at current levels to capitalize on their massive $27 billion Meta deal, which the market has irrationally ignored due to macro volatility. Hims & Hers Health (HIMS) presents a high-conviction buying opportunity near $22, as the stock is priced for legal risks that have largely been resolved through their Novo Nordisk partnership. Avoid "Old World" telecom giants like AT&T (T) and Verizon (VZ), as they face existential threats from satellite disruption like Starlink and Amazon Kuiper. For long-term growth in Tesla (TSLA) and Bitcoin (BTC), utilize a Dollar Cost Average (DCA) strategy to lower your cost basis while avoiding dangerous short-term leverage or margin. Focus on high-quality disruptive innovation and LEAPS (long-term options) rather than short-term trades to survive the current liquidity crunch and position for the 2030s.

NVIDIA (NVDA) is currently the most undervalued "Magnificent 7" stock with a massive $1 trillion revenue opportunity by 2027 that the market has yet to price in. Investors should capitalize on the current price disconnect caused by geopolitical noise, viewing the NVDA valuation as a high-conviction entry point for long-term AI demand. Tesla (TSLA) remains a primary "industry eraser" trade; look past short-term delivery fluctuations and focus on the upcoming Robotaxi launch and energy storage growth as major catalysts. Hims & Hers Health (HIMS) offers a significant recovery play at the $24 level, especially as future revenue guidance begins to reflect their strategic partnership with Novo Nordisk. For those seeking resilience against market volatility, Bitcoin (BTC) and MicroStrategy (MSTR) are viewed as fundamentally "too cheap" despite temporary liquidity crunches and macroeconomic headwinds.

Investors should prepare for continued volatility as interest rate cuts are likely delayed until late 2024, making capital preservation and avoiding excessive leverage the primary goals. Use the current market "panic" to look for value in Hims & Hers Health (HIMS), which offers a resilient subscription healthcare model that is currently being unfairly sold off due to macro fears. TransMedics Group (TMDX) is another high-conviction growth play that has become "dirt cheap" following recent aggressive selling, presenting a potential rebound opportunity. While Bitcoin (BTC) remains a long-term deflationary hedge, investors should remain cautious and wait for price stabilization near the $71,000 level before issuing new buy alerts. Avoid the traditional "60/40" portfolio trap by limiting exposure to U.S. Treasury Bonds, as rising national debt undermines their long-term stability despite their "risk-off" reputation.